Palestine
· Delayed Price · Currency is JOD · Price in USDBPC Statistics
Total Valuation
Birzeit Pharmaceuticals Company has a market cap or net worth of JOD 102.99 million. The enterprise value is 94.28 million.
| Market Cap | 102.99M |
| Enterprise Value | 94.28M |
Important Dates
The next estimated earnings date is Monday, November 11, 2024.
| Earnings Date | Nov 11, 2024 |
| Ex-Dividend Date | Apr 24, 2024 |
Share Statistics
Birzeit Pharmaceuticals Company has 38.76 million shares outstanding. The number of shares has increased by 1.00% in one year.
| Shares Outstanding | 38.76M |
| Shares Change (YoY) | +1.00% |
| Shares Change (QoQ) | +0.86% |
| Owned by Insiders (%) | 23.26% |
| Owned by Institutions (%) | n/a |
| Float | 23.90M |
Valuation Ratios
The trailing PE ratio is 53.02.
| PE Ratio | 53.02 |
| Forward PE | n/a |
| PS Ratio | 3.63 |
| PB Ratio | 1.49 |
| P/FCF Ratio | 30.93 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.16, with an EV/FCF ratio of 28.31.
| EV / Earnings | 49.22 |
| EV / Sales | 3.37 |
| EV / EBITDA | 18.16 |
| EV / EBIT | 22.47 |
| EV / FCF | 28.31 |
Financial Position
The company has a current ratio of 7.08
| Current Ratio | 7.08 |
| Quick Ratio | 5.46 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 183.29 |
Financial Efficiency
Return on equity (ROE) is 2.69% and return on invested capital (ROIC) is 3.62%.
| Return on Equity (ROE) | 2.69% |
| Return on Assets (ROA) | 3.02% |
| Return on Capital (ROIC) | 3.62% |
| Revenue Per Employee | 93,313 |
| Profits Per Employee | 6,385 |
| Employee Count | 300 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 2.03 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.54% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -8.54% |
| 50-Day Moving Average | 3.89 |
| 200-Day Moving Average | 4.06 |
| Relative Strength Index (RSI) | 44.79 |
| Average Volume (20 Days) | 25,645 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Birzeit Pharmaceuticals Company had revenue of JOD 27.99 million and earned 1.92 million in profits. Earnings per share was 0.05.
| Revenue | 27.99M |
| Gross Profit | 9.10M |
| Operating Income | 4.20M |
| Pretax Income | 2.42M |
| Net Income | 1.92M |
| EBITDA | 5.19M |
| EBIT | 4.20M |
| Earnings Per Share (EPS) | 0.05 |
Balance Sheet
| Cash & Cash Equivalents | 9.20M |
| Total Debt | n/a |
| Net Cash | 9.20M |
| Net Cash Per Share | 0.24 |
| Equity (Book Value) | 70.13M |
| Book Value Per Share | 1.78 |
| Working Capital | 39.60M |
Cash Flow
In the last 12 months, operating cash flow was 5.38 million and capital expenditures -2.05 million, giving a free cash flow of 3.33 million.
| Operating Cash Flow | 5.38M |
| Capital Expenditures | -2.05M |
| Free Cash Flow | 3.33M |
| FCF Per Share | 0.09 |
Margins
Gross margin is 32.52%, with operating and profit margins of 14.99% and 6.84%.
| Gross Margin | 32.52% |
| Operating Margin | 14.99% |
| Pretax Margin | 8.66% |
| Profit Margin | 6.84% |
| EBITDA Margin | 18.54% |
| EBIT Margin | 14.99% |
| FCF Margin | 11.90% |
Dividends & Yields
Birzeit Pharmaceuticals Company does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | -50.08% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 71.69% |
| Buyback Yield | -1.00% |
| Shareholder Yield | -1.00% |
| Earnings Yield | 1.89% |
| FCF Yield | 3.23% |
Stock Splits
The last stock split was on April 21, 2022. It was a forward split with a ratio of 2.
| Last Split Date | Apr 21, 2022 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |